Compare CYTK & ORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CYTK | ORA |
|---|---|---|
| Founded | 1997 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 6.9B |
| IPO Year | 2004 | 2004 |
| Metric | CYTK | ORA |
|---|---|---|
| Price | $62.51 | $111.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 8 |
| Target Price | $78.94 | ★ $117.13 |
| AVG Volume (30 Days) | ★ 1.7M | 628.7K |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | N/A | ★ 0.43% |
| EPS Growth | N/A | ★ 11.26 |
| EPS | N/A | ★ 2.18 |
| Revenue | $87,211,000.00 | ★ $944,248,000.00 |
| Revenue This Year | $361.33 | $11.57 |
| Revenue Next Year | $65.14 | $17.18 |
| P/E Ratio | ★ N/A | $50.84 |
| Revenue Growth | ★ 2609.26 | 6.07 |
| 52 Week Low | $29.31 | $61.58 |
| 52 Week High | $69.33 | $116.66 |
| Indicator | CYTK | ORA |
|---|---|---|
| Relative Strength Index (RSI) | 49.62 | 50.17 |
| Support Level | $59.37 | $107.09 |
| Resistance Level | $63.80 | $112.19 |
| Average True Range (ATR) | 2.56 | 2.77 |
| MACD | -0.44 | -0.44 |
| Stochastic Oscillator | 42.46 | 38.98 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Ormat Technologies Inc is engaged in the geothermal and recovered energy power business. It is engaged in three business segments: Electricity Segment. where the company develops, builds, owns and operates geothermal, solar PV and recovered energy-based power plants in the United States and geothermal power plants in other countries and sell the electricity generated. Product Segment includes designing, manufacturing and selling equipment for geothermal and recovered energy-based electricity generation and providing services relating to the engineering, procurement and construction of geothermal and recovered energy-based power plants. Energy Storage Segment includes owning and operating grid-connected which provide capacity, energy and ancillary services directly to the electric grid.